Atossa Therapeutics (United States)
company in Seattle, United States
ATOS Nasdaq
ISIN US04962H5063 SEC CIK 1488039 LEI 549300QRKP1JTNHD2366
Follow Atossa Therapeutics (United States)
Weekly email: filings, results
Net income
−$5.6M
+35.1% vs same quarter last year
EPS, diluted
−$0.56
+44.6% vs same quarter last year
Operating cash flow
−$5.5M
+8.1% vs same quarter last year
Operating income
−$5.9M
+36.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$34.8M |
| FY24 | - | −$25.5M |
| FY23 | - | −$30.1M |
| FY22 | - | −$27M |
| FY21 | - | −$20.6M |
| FY20 | - | −$17.8M |
| FY19 | - | −$17.2M |
| FY18 | - | −$11.4M |
| FY17 | - | −$8.1M |
| FY16 | - | −$6.4M |
| FY15 | $1.8K | −$15.8M |
| FY14 | $40.1K | −$14.7M |
| FY13 | $632.6K | −$10.8M |
| FY12 | $481.8K | −$5.1M |
| FY11 | $1.5K | −$3.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | - | - | - |
| FY23 | - | - | - |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | −7431.9% | −725746.2% | −896491.6% |
| FY14 | 100% | −30323% | −36518.8% |
| FY13 | 21.7% | −1704.9% | −1704.9% |
| FY12 | 86.4% | −1052% | −1054.3% |
| FY11 | −6379.3% | −228612.7% | −229484.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$29.8M |
| FY24 | −$21M |
| FY23 | −$21M |
| FY22 | −$20.8M |
| FY21 | −$16.5M |
| FY20 | −$11.6M |
| FY19 | −$9.1M |
| FY18 | −$9.1M |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | $0 |
| FY23 | $1.5M |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Atossa Therapeutics (United States)
- Healthcare median
Show the numbers
| Year | Atossa Therapeutics (United States) | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | −896491.6% | −37.8% |
| FY14 | −36518.8% | −35.5% |
| FY13 | −1704.9% | −37.1% |
| FY12 | −1054.3% | −29.1% |
| FY11 | −229484.5% | −27.9% |